Trial reportBMC health services research2021
Process evaluation for the Care Homes Independent Pharmacist Prescriber Study (CHIPPS).
Trial report in BMC health services research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Interventions for preventing falls in older people in care facilities.The Cochrane database of systematic reviews · 2025Pooled it
- Pooled it
- Pooled it
- Trial
- Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour change intervention to increase influenza vaccination uptake among care home staff in England.BMC health services research · 2025Trial
- What happens when pharmacist independent prescribers lead on medicine management in older people's care homes: a qualitative study.BMJ open · 2023Trial
- Evaluation of effectiveness and safety of pharmacist independent prescribers in care homes: cluster randomised controlled trial.BMJ (Clinical research ed.) · 2023Trial
- Developing a Theoretically Informed Strategy to Enhance Pharmacist-Led Deprescribing in Care Homes for Older People.Pharmacy (Basel, Switzerland) · 2025Article
- Service delivery and the role of clinical pharmacists in UK primary care for older people, including people with dementia: a scoping review.BMC primary care · 2025Article
- Article
- Determinants of implementing deprescribing for older adults in English care homes: a qualitative interview study.BMJ open · 2023Article
- Why the trial researcher matters: Day-to-day work viewed through the lens of normalization process theory.SSM. Qualitative research in health · 2023Article
- Enhancing deprescribing: A qualitative understanding of the complexities of pharmacist-led deprescribing in care homes.Health & social care in the community · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedicines management in care homes requires significant improvement. CHIPPS was a cluster randomised controlled trial to determine the effectiveness of integrating pharmacist independent prescribers into care homes to assume central responsibility for medicines management. This paper reports the parallel mixed-methods process evaluation.
methodIntervention arm consisted of 25 triads: Care homes (staff and up to 24 residents), General Practitioner (GP) and Pharmacist Independent Prescriber (PIP). Data sources were pharmaceutical care plans (PCPs), pharmacist activity logs, online questionnaires and semi-structured interviews. Quantitative data were analysed descriptively. Qualitative data were analysed thematically. Results were mapped to the process evaluation objectives following the Medical Research Council framework.
resultsPCPs and activity logs were available from 22 PIPs. Questionnaires were returned by 16 PIPs, eight GPs, and two care home managers. Interviews were completed with 14 PIPs, eight GPs, nine care home managers, six care home staff, and one resident. All stakeholders reported some benefits from PIPs having responsibility for medicine management and identified no safety concerns. PIPs reported an increase in their knowledge and identified the value of having time to engage with care home staff and residents during reviews. The research paperwork was identified as least useful by many PIPs. PIPs conducted medication reviews on residents, recording 566 clinical interventions, many involving deprescribing; 93.8% of changes were sustained at 6 months. For 284 (50.2%) residents a medicine was stopped, and for a quarter of residents, changes involved a medicine linked to increased falls risk. Qualitative data indicated participants noted increased medication safety and improved resident quality of life. Contextual barriers to implementation were apparent in the few triads where PIP was not known previously to the GP and care home before the trial. In three triads, PIPs did not deliver the intervention.
conclusionsThe intervention was generally implemented as intended, and well-received by most stakeholders. Whilst there was widespread deprescribing, contextual factors effected opportunity for PIP engagement in care homes. Implementation was most effective when communication pathways between PIP and GP had been previously well-established.
trial registrationThe definitive RCT was registered with the ISRCTN registry (registration number ISRCTN 17847169 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.